As genomics continues to scale, the industry is increasingly constrained not by sequencing capacity, but by data quality, workflow complexity, and inefficiencies in sample preparation. Pranav Patel, CEO of n6, is focused on addressing these bottlenecks by fundamentally rethinking how genomic data is generated at the source.
n6’s mission is clear: preserve the integrity of every sample while simplifying the path to high-quality data. At the core of this approach is a challenge to long-standing industry norms—particularly the reliance on legacy technologies such as PCR, originally developed decades before next-generation sequencing (NGS). While foundational, these tools were not designed for today’s scale and precision requirements, often introducing bias, artifacts, and inefficiencies.
Positioned within the library preparation segment, n6 plays a critical role in the genomics workflow, influencing outcomes across sequencing and downstream analysis. Patel emphasizes that decisions made during sample prep directly impact sequencing depth, cost, and analytical accuracy—making it a pivotal, yet often underestimated, stage in the genomics pipeline.
n6’s technology addresses one of the most persistent challenges in genomics: imperfect amplification. Traditional workflows tend to over-amplify to avoid data loss, leading to duplicates, artifacts, and distorted biological signals. Conversely, under-amplification risks losing valuable information entirely. n6 introduces a novel approach that enables precise, balanced amplification of DNA and RNA, eliminating both over- and under-amplification. The result is cleaner data, reduced bias, and more reliable downstream insights.
Beyond data quality, n6 is driving significant improvements in workflow efficiency. By removing non-value-added steps—such as repetitive cleanups and quantification processes—the company can reduce laboratory workload by 40–70%. This not only lowers costs and resource consumption but also minimizes opportunities for human error, supporting more reproducible outcomes. Importantly, this approach aligns with sustainability goals by reducing reagent use and plastic waste.
Patel also challenges conventional thinking around automation. Rather than simply accelerating existing manual processes, he advocates for workflow simplification as the true path to automation. Eliminating unnecessary steps altogether, rather than optimizing them, leads to more robust, scalable, and efficient systems.
Looking ahead to the next phase of genomics and multi-omics, Patel highlights a shift in where the industry must focus. While sequencing costs have dropped dramatically—unlocking new levels of scale—the bottleneck has moved upstream to sample preparation, where processes remain labor-intensive and difficult to multiplex. Addressing this imbalance will be critical to achieving true economic scale in genomics.
A key theme for the future is collaboration across the ecosystem. Patel stresses that scaling genomics will require tighter integration between technology providers. Rather than fragmented solutions, the industry must move toward fully validated, end-to-end workflows, reducing the burden on researchers to piece together and validate complex pipelines themselves.
As a Tech Partner at Next Gen Omics US 2026, n6 represents a new wave of innovation focused on data quality, workflow simplification, and scalable genomics infrastructure. By reengineering foundational processes, the company is helping enable a future where genomic insights are not only more accurate, but also more accessible and efficient to generate.
